Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
| Autor: | Elizabeth A. Griffiths, Martha Wadleigh, Pamela S. Becker, Mark B. Geyer, Peter Westervelt, Avyakta Kallam, Sumithira Vasu, Rita Cool, Ivana Gojo, Rachel P. Rosovsky, Laura M Alwan, Anna Brown, Dwight D. Kloth, Lia Perez, Gary H. Lyman, Peter T. Curtin, Hope S. Rugo, Eric H. Kraut, Kimo Bachiashvili, Wajih Zaheer Kidwai, Sudipto Mukherjee, Vivek Roy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy business.industry Anemia medicine.medical_treatment Thrombopoietin mimetics Cancer Context (language use) Neutropenia medicine.disease Article 03 medical and health sciences Haematopoiesis 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Pandemic medicine 030212 general & internal medicine business |
| Zdroj: | J Natl Compr Canc Netw |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2020.7610 |
| Popis: | Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of cancer. In the context of pandemic SARS-CoV-2 infection, patients with cancer have been identified as a group at high risk of morbidity and mortality from this infection. Our subcommittee of the NCCN Hematopoietic Growth Factors Panel convened a voluntary group to review the potential value of expanded use of such growth factors in the current high-risk environment. Although recommendations are available on the NCCN website in the COVID-19 Resources Section (https://www.nccn.org/covid-19/), these suggestions are provided without substantial context or reference. Herein we review the rationale and data underlying the suggested alterations to the use of hematopoietic growth factors for patients with cancer in the COVID-19 era. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|